Latest Regulatory Filings News

Gullewa Limited reported a positive cash flow quarter ending March 2025 and increased its ownership in Central Iron Ore Limited to 54.46%, signaling strategic consolidation in its iron ore interests.

InteliCare Holdings reported a net operating cash outflow of AUD 447,000 for Q1 2025 but remains confident in sustaining operations through active cash management and potential capital raises.

Aguia Resources reported a challenging Q1 2025 cash flow, ending the quarter with just AUD 1.2 million in cash and less than half a quarter of funding available. The board remains confident in raising capital to sustain mining and exploration activities at Santa Barbara Mine.

Energy Technologies Limited reported a 6.8% decline in quarterly cash receipts and a 37.5% rise in net operating outflows for 3Q FY2025, prompting a strategic review of its capital structure to support future growth.

Avecho Biotechnology has inked a decade-long exclusive licensing agreement with Sandoz for its pharmaceutical-grade cannabidiol capsule targeting insomnia in Australia, backed by a US$3 million upfront payment and promising milestone and royalty streams.

Ronin Resources has made significant strides in its La Punilla gold-silver project in Argentina, while navigating socio-political hurdles in Colombia and refining its lithium exploration efforts in Canada. The company maintains a solid cash position as it pursues new business opportunities.

FirstWave Cloud Technology reported a mixed Q3 FY25 with declining cash reserves and ARR but secured a strategic AWS-funded partnership to accelerate cloud service adoption.

Atomos Limited reported a $2.3 million operating cash outflow in Q3 FY25 amid seasonal softness and tariff challenges, while announcing a leadership change and a bold expansion into new product categories beyond its core monitor-recorder business.

Little Green Pharma reported a robust 40% revenue increase for FY25, driven by strong European sales and the strategic acquisition of Health House. The company also advanced clinical research and secured new therapy funding, positioning itself for continued growth.

Tissue Repair Limited reports progress in its Phase 3 clinical trials for TR987® despite enrollment delays caused by US regulatory disruptions, while TR Pro+® sales hit record highs and manufacturing scale-up advances.

Alterity Therapeutics reports compelling Phase 2 clinical trial results for ATH434 in Multiple System Atrophy, alongside a significant capital raise strengthening its financial position for upcoming regulatory milestones.

Impact Minerals Limited reported a solid cash position of A$3.75 million at quarter-end, supported by a recent equity raise that extends its funding runway to nearly four quarters despite ongoing exploration expenditures.